NCT03778931: Phase 3 Trial of Elacestrant vs. Standard of Care for the Treatment of Patients With ER+/HER2- Advanced Breast Cancer

Breast Cancer Type: HR+ & HER2-negative
Hormone Mutations: ER+
Other Mutations: ESR1
Breast Cancer Tissue: 
Recruitment Status: Active, not recruiting
Phase 3
Drug Category: Endocrine (Hormone) Therapy

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases: 
Additional Notes: Patients must have an ESR1 mutation; Patients must have received prior treatment with a CDK 4/6 inhibitor (e.g. Ibrance) with hormone therapy
Exclusions: Patients who have received more than 1 line of chemotherapy in the metastatic setting

Comments are closed.

Up ↑